• News
  • SAN DIEGO
  • BioTech

Targeson receives $776,800 in year 2 of SBIR grant

San Diego's Targeson Inc. announced it has received the Notice of Award for year 2 of the company’s 2R44 grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health.

This project, entitled “Selectin Targeted Ultrasound Contrast Agents for Detection of Acute Coronary Syndrome,” will explore the use of Targeson’s targeted microspheres as a diagnostic imaging test for detecting recent myocardial ischemia.

Research will be conducted in conjunction with professor Anthony DeMaria, M.D., at the University of California, San Diego.

Current methods for assessing the extent of cardiac ischemic injury in an acute setting offer limited sensitivity and specificity, which leads to both under- and over-treatment of patients with suspected acute coronary syndrome.

The aim of this grant will be to investigate a novel microsphere contrast agent targeted to a molecular marker of recent ischemia, enabling visualization of recent myocardial ischemia using echocardiography (cardiac ultrasound).

Targeson has identified a novel targeting agent and developed a biocompatible coupling chemistry suitable for eventual translation to human use. Target-binding activity and efficacy will be studied in animal models to characterize and validate the imaging agent. Initial safety studies will be performed in animal models to enable a future investigational new drug submission.

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Targeson Inc.

Company Website

3550 General Atomics Ct. MS, 02-606
San Diego, CA 92121

Targeson Inc. Executive(s):

Joshua Rychak

  • Co-Founder
Subscribe Today!